• Increase font size
  • Default font size
  • Decrease font size

Update: Partner for Glucose Breath Test?

Print E-mail
By Peter DePalma   
Tuesday, 04 May 2010 09:05
PositiveID Corporation (Nasdaq: PSID) is developing the non-invasive Easy Check breath glucose analysis system and sources are telling BioMedReports that a bigger company or two have taken an interest in partnering with them for a piece of the huge diabetic market that the test would open up. As reported earlier, this unique, non-invasive glucose detection system measures the levels of acetone in a patient’s exhaled breath.
It combines a proprietary chemical mixture with exhaled breath, which creates a new molecular compound that can be measured with the Company’s patent-pending technology.

Industry sources say a significant partnership may be very close to completion and public announcement. Such news would not only help validate the technology, but would also likely send PSID's tightly floated shares upward.

In the U.S. alone, 23.6 million people (7.8% of the total population) have diabetes. The PSID device  could eliminate a patient’s need to prick his or her finger multiple times per day to get a blood sugar reading.

Disclosure: Long PSID





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 27 minutes ago Brains of Combat Vets Exposed to Roadside Bombs Likened to Those in Athletes http://t.co/uoYocb4Y
about 54 minutes ago Focus on Perifosine May Shift For AEterna Zenatis Investors: Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) is an oncol... http://t.co/2ZZQbrSG
about 3 hours ago NHS education reforms 'lack detail' http://t.co/YiUKVEsS
about 3 hours ago Molecular 'on-off' switch for Parkinson's disease discovered http://t.co/wZ1N0xhq
about 3 hours ago Alnylam and PBL Sign License Agreement for Baulcombe & Hamilton RNAi Patent http://t.co/CnJ8fKok
about 3 hours ago Roche's dalcetrapib failure fuels HDL debate, but CETP not done yet http://t.co/8H9JRnp9
about 3 hours ago Modest Gains Vanish As Stocks Reverse Lower http://t.co/AXlpfiAP
about 3 hours ago Reading: One More Reason the Market's Pullback is Not Over http://t.co/iSZ0oYUq

navigation

Free Phone Trade Alerts

Benzinga.com supporter Seeking Alpha Certified